|
1.
|
Crabb SJ, Patsios D, Sauerbrei E, Ellis
PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L
and Laurie SA: Tumor cavitation: impact on objective response
evaluation in trials of angiogenesis inhibitors in non-small-cell
lung cancer. J Clin Oncol. 27:404–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3.
|
Azzoli CG, Baker S Jr, Temin S, et al:
American Society of Clinical Oncology Clinical Practice Guideline
update on chemo-therapy for stage IV non-small-cell lung cancer. J
Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar
|
|
4.
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
5.
|
Dudek AZ and Mahaseth H: Circulating
angiogenic cytokines in patients with advanced non-small cell lung
cancer: correlation with treatment response and survival. Cancer
Invest. 23:193–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Laack E, Scheffler A, Burkholder I,
Boeters I, Andritzky B, Schuch G, Görn M, Vohwinkel G, Edler L,
Fiedler W and Hossfeld DK: Pretreatment vascular endothelial growth
factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels
in patients with metastatic non-small cell lung cancer (NSCLC).
Lung Cancer. 50:51–58. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Nishi M, Abe Y, Tomii Y, Tsukamoto H,
Kijima H, Yamazaki H, Ohnishi Y, Iwasaki M, Inoue H, Ueyama Y and
Nakamura M: Cell binding isoforms of vascular endothelial growth
factor-A (VEGF189) contribute to blood flow-distant metastasis of
pulmonary adenocarcinoma. Int J Oncol. 26:1517–1524. 2005.
|
|
8.
|
Seto T, Higashiyama M, Funai H, Imamura F,
Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic
value of expression of vascular endothelial growth factor and its
flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung
Cancer. 53:91–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Shimanuki Y, Takahashi K, Cui R, Hori S,
Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular
endothelial growth factor in the prediction of angiogenesis and
prognosis for non-small cell lung cancer. Lung. 183:29–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wagstaff AJ, Keam SJ and McCormack PL:
Bevacizumab plus platinum-based chemotherapy: in advanced non-small
cell lung cancer. BioDrugs. 23:187–196. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Dai M, Luo RC, Zheng DY, Lü CW and Ding
XM: Effects of bevacizumab and cisplatin on human lung
adenocarcinoma A549/DDP xenografts in nude mice. Nan Fang Yi Ke Da
Xue Xue Bao. 27:1402–1405. 2007.PubMed/NCBI
|
|
12.
|
Lee FY, Covello KL, Castaneda S, Hawken
DR, Kan D, Lewin A, Wen ML, Ryseck RP, Fairchild CR, Fargnoli J and
Kramer R: Synergistic antitumor activity of ixabepilone
(BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Clin Cancer Res. 14:8123–8131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ,
McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE and
Heymach JV: Distinct patterns of cytokine and angiogenic factor
modulation and markers of benefit for vandetanib and/or
chemo-therapy in patients with non-small-cell lung cancer. J Clin
Oncol. 28:193–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Jiang BH, Agani F, Passaniti A and Semenza
GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1)
and transcription of genes encoding vascular endothelial growth
factor and enolase 1: involvement of HIF-1 in tumor progression.
Cancer Res. 57:5328–5335. 1997.
|
|
15.
|
Rak J, Filmus J, Finkenzeller G, Grugel S,
Marme D and Kerbel RS: Oncogenes as inducers of tumor angiogenesis.
Cancer Metastasis Rev. 14:263–277. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Semenza GL: Hypoxia, clonal selection, and
the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol.
35:71–103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
López-Barneo J, del Toro R, Levitsky KL,
Chiara MD and Ortega-Sáenz P: Regulation of oxygen sensing by ion
channels. J Appl Physiol. 96:1187–1195. 2004.PubMed/NCBI
|
|
18.
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996.PubMed/NCBI
|
|
19.
|
Ferrara N and Bunting S: Vascular
endothelial growth factor, a specific regulator of angiogenesis.
Curr Opin Nephrol Hypertens. 5:35–44. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Neufeld G, Cohen T, Gengrinovitch S and
Poltorak Z: Vascular endothelial growth factor (VEGF) and its
receptors. FASEB J. 13:9–22. 1999.PubMed/NCBI
|
|
22.
|
Carmeliet P, Moons L, Dewerchin M, Mackman
N, Luther T, Breier G, Ploplis V, Muller M, Nagy A, Plow E, Gerard
R, Edgington T, Risau W and Collen D: Insights in vessel
development and vascular disorders using targeted inactivation and
transfer of vascular endothelial growth factor, the tissue factor
receptor, and the plasminogen system. Ann NY Acad Sci. 811:191–206.
1997. View Article : Google Scholar
|
|
23.
|
Ferrara N, Carver-Moore K, Chen H, Dowd M,
Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ and Moore MW:
Heterozygous embryonic lethality induced by targeted inactivation
of the VEGF gene. Nature. 380:439–442. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Olson TA, Mohanraj D, Carson LF and
Ramakrishnan S: Vascular permeability factor gene expression in
normal and neoplastic human ovaries. Cancer Res. 54:276–280.
1994.PubMed/NCBI
|
|
25.
|
Senger DR, van de Water L, Brown LF, Nagy
JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF:
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer
Metastasis Rev. 12:303–324. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Holash J, Davis S, Papadopoulos N, et al:
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl
Acad Sci USA. 99:11393–11398. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kim KJ, Li B, Winer J, Armanini M, Gillett
N, Phillips HS and Ferrara N: Inhibition of vascular endothelial
growth factor-induced angiogenesis suppresses tumour growth in
vivo. Nature. 362:841–844. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Prewett M, Huber J, Li Y, Santiago A,
O’Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L,
Bohlen P and Hicklin DJ: Antivascular endothelial growth factor
receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor
angiogenesis and growth of several mouse and human tumors. Cancer
Res. 59:5209–5218. 1999.
|
|
29.
|
Loo WT, Fong JH, Cheung MN and Chow LW:
The efficacy of paclitaxel on solid tumour analysed by ATP
bioluminescence assay and VEGF expression: a translational research
study. Biomed Pharmacother. 59(Suppl 2): 337–339. 2005. View Article : Google Scholar
|
|
30.
|
Plunkett W, Huang P, Xu YZ, Heinemann V,
Grunewald R and Gandhi V: Gemcitabine: metabolism, mechanisms of
action, and self-potentiation. Semin Oncol. 22:3–10.
1995.PubMed/NCBI
|
|
31.
|
Krause S, Förster Y, Kraemer K, Fuessel S,
Kotzsch M, Schmidt U, Wirth MP, Meye A and Schwenzer B: Vascular
endothelial growth factor antisense pretreatment of bladder cancer
cells significantly enhances the cytotoxicity of mitomycin C,
gemcitabine and cisplatin. J Urol. 174:328–331. 2005. View Article : Google Scholar
|
|
32.
|
Förster Y, Meye A, Krause S and Schwenzer
B: Antisense-mediated VEGF suppression in bladder and breast cancer
cells. Cancer Lett. 212:95–103. 2004.PubMed/NCBI
|
|
33.
|
Maxwell PH and Ratcliffe PJ: Oxygen
sensors and angiogenesis. Semin Cell Dev Biol. 13:29–37. 2002.
View Article : Google Scholar : PubMed/NCBI
|
